Codagenix Inc

Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells. The highly attenuated viruses make excellent vaccines or oncolytics against solid tumors. Codagenix represents the next wave in vaccine technology, untethered from traditional, time-consuming and unpredictable approaches to attenuating viruses

Live-attenuated vaccine design,infectious disease,synthetic biology,virology,clinical trials,vaccines,influenza,rsv,dengue,and oncolytics

Codagenix inc operates in the Biotechnology research industry.

Codagenix inc's revenue is 11m - 100m

Codagenix inc has 11 - 50 employees.